Neo-MASCT (HRYZ Biotech/The First People's Hospital of Lianyungang)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameNeo-MASCT (HRYZ Biotech/The First People's Hospital of Lianyungang)
Drug Alias NameNeo-MASCT (HRYZ Biotech)
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocytes stimulants
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesHRYZ Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHRYZ Biotech Co LtdThe First People'S Hospital Of Lianyungang
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A